携疟原虫 1 型对伯氨喹敏感性的基因分析：一位复发型间日疟患者的案例报告
Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria.
机构信息
University of California, San Diego, La Jolla, CA, USA
出版信息
Emerg Infect Dis. 2013 May;19(5):802-5. doi: 10.3201/eid1905.121852.
Abstract
Patients with Plasmodium vivax malaria are treated with primaquine to prevent relapse infections. We report primaquine failure in a patient with 3 relapses without any possibility of re-infection. Using whole genome sequencing of the relapsing parasite isolates, we identified single nucleotide variants as candidate molecular markers of resistance.
摘要
患有间日疟原虫疟疾的患者使用伯氨喹来预防复发感染。我们报告了一名患者在没有再次感染可能的情况下出现 3 次复发的伯氨喹治疗失败。通过对复发寄生虫分离株进行全基因组测序，我们确定了单核苷酸变异作为耐药性的候选分子标记。
相似文献
1
Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria.携疟原虫 1 型对伯氨喹敏感性的基因分析：一位复发型间日疟患者的案例报告
Emerg Infect Dis. 2013 May;19(5):802-5. doi: 10.3201/eid1905.121852.
2
Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.从西非感染的间日疟原虫多次复发与 CYP2D6 代谢不良变异体相关：病例报告。
BMC Infect Dis. 2019 Aug 9;19(1):704. doi: 10.1186/s12879-019-4357-9.
3
In vivo therapeutic efficacy of chloroquine alone or in combination with primaquine against vivax malaria in Kolkata, West Bengal, India, and polymorphism in pvmdr1 and pvcrt-o genes.印度西孟加拉邦加尔各答地区氯喹单药或联合伯氨喹治疗间日疟的体内疗效及 pvmdr1 和 pvcrt-o 基因多态性。
Antimicrob Agents Chemother. 2013 Mar;57(3):1246-51. doi: 10.1128/AAC.02050-12. Epub 2012 Dec 21.
4
Management of relapsing Plasmodium vivax malaria.复发性间日疟的管理
Expert Rev Anti Infect Ther. 2016 Oct;14(10):885-900. doi: 10.1080/14787210.2016.1220304. Epub 2016 Aug 31.
5
Imported tertian malaria resistant to primaquine.对伯氨喹耐药的输入性间日疟
Korean J Intern Med. 1999 Jul;14(2):86-9. doi: 10.3904/kjim.1999.14.2.86.
6
Studies on a primaquine-tolerant strain of Plasmodium vivax from Brazil in Aotus and Saimiri monkeys.对来自巴西的间日疟原虫耐伯氨喹株在夜猴和松鼠猴体内的研究。
J Parasitol. 1997 Aug;83(4):739-45.
7
Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.细胞色素 P450 2D6 活性基因型和表型受损与磷酸萘酚喹治疗潜伏性间日疟原虫疟疾的疗效相关性研究。
JAMA Netw Open. 2018 Aug 3;1(4):e181449. doi: 10.1001/jamanetworkopen.2018.1449.
8
Is primaquine useful and safe as true exo-erythrocytic merontocidal, hypnozoitocidal and gametocidal antimalarial drug?伯氨喹作为真正的杀红细胞外期裂殖体、杀休眠子及杀配子体的抗疟药，是否有用且安全？
Salud Publica Mex. 1999 Sep-Oct;41(5):410-9. doi: 10.1590/s0036-36341999000500010.
9
Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata.对恶性疟原虫的基因分型显示，加尔各答既有短期潜伏期又有长期潜伏期的复发模式。
PLoS One. 2012;7(7):e39645. doi: 10.1371/journal.pone.0039645. Epub 2012 Jul 13.
10
Diagnostic and therapeutic pitfalls associated with primaquine-tolerant Plasmodium vivax.与耐伯氨喹间日疟原虫相关的诊断和治疗陷阱。
J Clin Microbiol. 2005 Feb;43(2):978-81. doi: 10.1128/JCM.43.2.978-981.2005.
引用本文的文献
1
Quest for malaria management using natural remedies.探索使用天然药物治疗疟疾。
Front Pharmacol. 2024 Jun 26;15:1359890. doi: 10.3389/fphar.2024.1359890. eCollection 2024.
2
Novel highly-multiplexed AmpliSeq targeted assay for genetic surveillance use cases at multiple geographical scales.新型高通量 AmpliSeq 靶向检测方法，可用于多个地理尺度的遗传监测应用案例。
Front Cell Infect Microbiol. 2022 Aug 11;12:953187. doi: 10.3389/fcimb.2022.953187. eCollection 2022.
3
Whole Genome Sequencing Contributions and Challenges in Disease Reduction Focused on Malaria.全基因组测序在以疟疾为重点的疾病防控中的贡献与挑战
Biology (Basel). 2022 Apr 13;11(4):587. doi: 10.3390/biology11040587.
4
A molecular barcode to inform the geographical origin and transmission dynamics of Plasmodium vivax malaria.一种分子条码，用于指示间日疟原虫疟疾的地理来源和传播动态。
PLoS Genet. 2020 Feb 13;16(2):e1008576. doi: 10.1371/journal.pgen.1008576. eCollection 2020 Feb.
5
The genomic architecture of antimalarial drug resistance.抗疟药耐药性的基因组结构。
Brief Funct Genomics. 2019 Sep 24;18(5):314-328. doi: 10.1093/bfgp/elz008.
6
Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor.细胞色素 P450 2D6 谱及其与在巴布亚新几内亚和东帝汶部署的澳大利亚国防军人员伯氨喹抗复发治疗结局的关系。
Malar J. 2019 Apr 18;18(1):140. doi: 10.1186/s12936-019-2774-2.
7
Effects of MAO-A and CYP450 on primaquine metabolism in healthy volunteers.单胺氧化酶A和细胞色素P450对健康志愿者中伯氨喹代谢的影响。
Parasitol Res. 2019 Mar;118(3):1011-1018. doi: 10.1007/s00436-019-06210-3. Epub 2019 Jan 31.
8
A novel immortalized hepatocyte-like cell line (imHC) supports in vitro liver stage development of the human malarial parasite Plasmodium vivax.一种新型永生化肝细胞样细胞系（imHC）支持体外人类疟原虫 vivax 的肝期发育。
Malar J. 2018 Jan 25;17(1):50. doi: 10.1186/s12936-018-2198-4.
9
Molecular and immunological analyses of confirmed Plasmodium vivax relapse episodes.间日疟原虫确诊复发病例的分子和免疫学分析。
Malar J. 2017 May 30;16(1):228. doi: 10.1186/s12936-017-1877-x.
10
A chimeric protein-based malaria vaccine candidate induces robust T cell responses against Plasmodium vivax MSP1.一种基于嵌合蛋白的疟疾候选疫苗可诱导针对间日疟原虫 MSP1 的强烈 T 细胞反应。
Sci Rep. 2016 Oct 6;6:34527. doi: 10.1038/srep34527.
本文引用的文献
1
The malaria parasite Plasmodium vivax exhibits greater genetic diversity than Plasmodium falciparum.疟原虫恶性疟原虫比间日疟原虫表现出更大的遗传多样性。
Nat Genet. 2012 Sep;44(9):1046-50. doi: 10.1038/ng.2373. Epub 2012 Aug 5.
2
CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine.CYP450 表型分析和 8-氨基喹啉类抗疟药物伯氨喹代谢产物的精确质量鉴定。
Malar J. 2012 Aug 2;11:259. doi: 10.1186/1475-2875-11-259.
3
Relapse of imported Plasmodium vivax malaria is related to primaquine dose: a retrospective study.输入性间日疟原虫疟疾复发与伯氨喹剂量的关系：一项回顾性研究
Malar J. 2012 Jun 22;11:214. doi: 10.1186/1475-2875-11-214.
4
Relapse of imported vivax malaria despite standard-dose primaquine therapy: an investigation with molecular genotyping analyses.尽管采用标准剂量的伯氨喹治疗，输入性间日疟仍有复发：一项采用分子基因分型分析的调查。
Clin Microbiol Infect. 2012 Jul;18(7):E232-4. doi: 10.1111/j.1469-0691.2012.03820.x. Epub 2012 Mar 27.
5
Human genetic variation is associated with Plasmodium falciparum drug resistance.人类遗传变异与恶性疟原虫抗药性有关。
J Infect Dis. 2011 Dec 1;204(11):1772-8. doi: 10.1093/infdis/jir629. Epub 2011 Oct 12.
6
The international limits and population at risk of Plasmodium vivax transmission in 2009.2009 年按蚊传播间日疟原虫的国际界限和危险人群。
PLoS Negl Trop Dis. 2010 Aug 3;4(8):e774. doi: 10.1371/journal.pntd.0000774.
7
Resistance to therapies for infection by Plasmodium vivax.间日疟原虫感染治疗的耐药性。
Clin Microbiol Rev. 2009 Jul;22(3):508-34. doi: 10.1128/CMR.00008-09.
8
New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance.间日疟原虫疟疾的新进展：重症疾病与氯喹耐药性的上升
Curr Opin Infect Dis. 2009 Oct;22(5):430-5. doi: 10.1097/QCO.0b013e32832f14c1.
9
Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione.恶性疟原虫多药耐药相关蛋白（PfMRP）的破坏会改变其适应性以及抗疟药物和谷胱甘肽的转运。
J Biol Chem. 2009 Mar 20;284(12):7687-96. doi: 10.1074/jbc.M806944200. Epub 2008 Dec 31.
10
Pharmacogenetics of cytochromes P450 in tropical medicine.热带医学中细胞色素P450的药物遗传学
Curr Drug Targets. 2006 Dec;7(12):1709-19. doi: 10.2174/138945006779025347.
Zotero 插件